Oncoinvent ASA (ONCO), a clinical-stage radiopharmaceutical company, on Thursday announced completing 50% enrollment in the Phase 2 trial evaluating Radspherin in treating peritoneal metastasis of ovarian cancer.
The company's lead product candidate Radspherin consists of calcium carbonate microparticles enclosing a radium-224 core to facilitate the targeted radioactive lysing of cancer cells. The therapy leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation, and is designed to prevent or delay peritoneal metastasis.
The randomized, controlled Phase 2 trial was initiated to assess the safety and efficacy of Radspherin in patients who have undergone complete surgical resection and pre-operative chemotherapy, in comparison to patients treated with surgery and chemotherapy alone. The primary endpoint was set at the rate of progression free survival (PFS) among treated patients. The Phase 1/2 trial previously showed promising results with a good safety profile for the therapy.
The Phase 2 trial has recruited 28 patients of ovarian cancer with peritoneal metastasis this year, already surpassing the enrollment numbers in 2025. This brings total enrollment to 54 patients, who are expected to be dosed across testing sites in the U.S., Spain, Norway, Belgium, UK and Italy.
Radspherin is also being evaluated in the treatment of peritoneal metastasis in colorectal cancer.
ONCIN.OL is currently trading on the Oslo Stock Exchange at NOK 50.20, up 13.20%.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.